Caerus Investment Advisors LLC Decreases Stake in Bristol Myers Squibb Company $BMY

Caerus Investment Advisors LLC lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 31.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,217 shares of the biopharmaceutical company’s stock after selling 10,665 shares during the period. Bristol Myers Squibb comprises 0.6% of Caerus Investment Advisors LLC’s investment portfolio, making the stock its 29th biggest holding. Caerus Investment Advisors LLC’s holdings in Bristol Myers Squibb were worth $1,408,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after purchasing an additional 2,743,759 shares during the last quarter. State Street Corp grew its stake in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares in the last quarter. Geode Capital Management LLC increased its holdings in Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares during the last quarter. Norges Bank acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at $1,947,272,000. Finally, AQR Capital Management LLC raised its stake in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald restated a “neutral” rating and set a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Royal Bank Of Canada raised their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a report on Friday. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Raymond James Financial restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $63.24.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Strong Q2 results and raised guidance: Bristol Myers reported adjusted EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion versus expectations of $11.74 billion. Revenue rose 5.7% year over year. Management raised 2026 EPS guidance to $6.75-$7.00 and revenue guidance to $49-$50 billion, both above Wall Street estimates. Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
• Positive Sentiment: Growth products are gaining momentum: Eliquis sales, along with newer medicines including Camzyos, Reblozyl, Opdivo Qvantig and Breyanzi, drove results. The growth portfolio now contributes roughly 60% of revenue, helping offset pressure from older products. Bristol-Myers Squibb Q2 2026 earnings call transcript
• Positive Sentiment: Several analysts raised targets: JPMorgan lifted its target from $67 to $73 and maintained an “overweight” rating, while Truist raised its target from $65 to $70 and reaffirmed “buy.” These revisions suggest analysts see additional upside following the earnings beat.
• Neutral Sentiment: Valuation is back in focus: Analysts note that BMY’s strong performance and recent rally have reduced the margin of safety, despite relatively attractive valuation and dividend support. RBC raised its target to $64 but retained a “sector perform” rating, implying the shares may remain range-bound. Bristol-Myers Squibb’s Catalyst Delays May Keep Stock Range-Bound, RBC Says
• Negative Sentiment: Pipeline timing and legacy declines remain risks: Delayed readouts or launches for Milvexian and Cobenfy, along with declines in older medicines such as Opdivo, could temper the growth outlook and postpone upcoming catalysts.
• Negative Sentiment: Bearish options activity: Traders purchased 44,620 put options, about 77% above typical daily volume, signaling increased hedging or speculation on downside risk.

Bristol Myers Squibb Stock Up 0.9%

Bristol Myers Squibb stock opened at $65.44 on Friday. The company has a market capitalization of $133.62 billion, a P/E ratio of 14.41, a PEG ratio of 0.19 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $65.66. The stock has a 50-day simple moving average of $58.02 and a 200-day simple moving average of $58.34.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 69.75% and a net margin of 18.87%.The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.88 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.